Gemcitabine After Surgery Prevents Bladder Cancer Recurrence
Clinical Impact
2018
SWOG S0337 showed that a single intravesical dose of gemcitabine administered immediately after transurethral tumor removal reduces bladder cancer recurrence by approximately 30%—changing urology guidelines worldwide.
Recent Breakthroughs
15-Year Results from SWOG’s S0016 Study Suggest Follicular Lymphoma Is Curable
A new long-term study challenges the belief that advanced follicular lymphoma is...
SWOG Cancer Research Network Celebrates 70 Years
SWOG Cancer Research Network marks its 70th year having enrolled nearly a...
New Immunotherapy Combination Standard for Hodgkin Lymphoma
The SWOG S1826 trial established nivolumab plus AVD chemotherapy as the new...
Practice-Influential Trials Reach 82 and 14 Drug Approvals
By 2024, SWOG-led research had produced 82+ practice-influential trials and contributed to...
Let’s advance cancer research, together.
Since our founding in 1993, we’ve harnessed answers to cancers through clinical trials. Join us to fuel the latest and best - or peruse our programs to apply for funding.
Robert Krouse, MD
Co-Chair, SWOG Palliative Care Committee